

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Diamond Animal Health, Inc.	
USDA Vet Biologics Establishment Number	213	
Product Code	1181.20	
True Name	Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3- Respiratory Syncytial Virus Vaccine, Modified Live Virus	
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Diamond Animal Health, Inc. Titanium 5 - Elanco Animal Health - Diamond Animal Health, Inc. Titanium 5 - Elanco Salud Animal, S.A. de C.V Diamond Animal Health, Inc. Titanium 5 - Elanco US, Inc Diamond Animal Health, Inc. Titanium 5 - Elanco, Division Eli Lilly Canada, Inc Diamond Animal Health, Inc. Titanium 5 - Virbac México S.A. de C.V.	
Date of Compilation Summary	August 16, 2021	

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

213 1181.20 Page 1 of 9

Study Type	Efficacy	
Pertaining to	Bovine Virus Diarrhea Type 1	
Study Purpose	To demonstrate effectiveness against disease caused by bovine	
	virus diarrhea type 1	
Product Administration	1 dose to calves 6-8 months of age.	
Study Animals	Bovine	
Challenge Description	BVDV NY-1 Strain non-cytopathic Type 1b	
Interval observed after		
challenge		
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.	
USDA Approval Date	July 14, 1998	

213 1181.20 Page 2 of 9

Study Type	Efficacy	
Pertaining to	Bovine Virus Diarrhea Virus (BVDV) Type 2	
Study Purpose	To demonstrate effectiveness against disease caused by bovine	
	virus diarrhea type 2	
Product Administration		
Study Animals	Bovine	
Challenge Description	BVDV Type 2a strain 890	
Interval observed after		
challenge		
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.	
USDA Approval Date	July 14, 1998	

213 1181.20 Page 3 of 9

Study Type	Efficacy	
Pertaining to	Infectious Bovine Rhinotracheitis (IBR) Virus	
Study Purpose	To demonstrate effectiveness against disease caused by infectious	
	bovine rhinotracheitis virus.	
Product Administration	1 dose to calves 6-8 months of age.	
Study Animals	Bovine	
Challenge Description		
Interval observed after		
challenge		
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.	
USDA Approval Date	July 13, 1998	

213 1181.20 Page 4 of 9

Study Type	Efficacy	
Pertaining to	Infectious Parainfluenza ₃ (PI ₃) Virus	
Study Purpose	To demonstrate effectiveness against disease caused by infectious	
	Parainfluenza ₃ Virus	
Product Administration	1 dose to calves 6-8 months of age.	
Study Animals	Bovine	
Challenge Description		
Interval observed after		
challenge		
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.	
USDA Approval Date	May 15, 1998	

213 1181.20 Page 5 of 9

Study Type	Efficacy	
Pertaining to	Bovine Respiratory Syncytial Virus (BRSV)	
Study Purpose	To demonstrate effectiveness against disease caused by infectious	
	Bovine Respiratory Syncytial Virus	
Product Administration	1 dose to calves 6-8 months of age.	
Study Animals	Bovine	
Challenge Description	BRSV Strain 375	
Interval observed after		
challenge		
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.	
USDA Approval Date	September 20, 1993	

213 1181.20 Page 6 of 9

Study Type	Safety
Pertaining to	ALL
Study Purpose	Demonstrate safety of product under typical use conditions
Product Administration	One dose
Study Animals	Bovine
Challenge Description	NA
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	July 13, 1998

213 1181.20 Page 7 of 9

Study Type	Safety				
Pertaining to	ALL				
Study Purpose	To demonstrate safety in pregnant cows and calves nursing				
	pregnant cows				
Product	Two doses administered subcutaneously to heifers and cows, 1				
Administration	dose prior to breeding and 1 dose during pregnancy at different				
	trimesters. Heifers and cows were confirmed to be pregnant at				
	administration du				
Study Animals	Heifers and cows-	-separa	ate groups vaccina	ted during each trimester.	
	Similar sized grou	ıps in	each trimester wer	re maintained as controls.	
Challenge Description	NA				
Interval observed after			-	ding vaccination through	
challenge				nrough 4 weeks of age.	
Results	Summary of Calv	_			
	(Normal calves de	elivere	ed/Total deliveries)	
		I			
	Trimester		einates	Controls	
	1		208 (96%)	205/213 (96%)	
	2		313 (96%)	293/308 (95%)	
	3		205 (94%)	195/208 (94%)	
	Total	695/	726 (96%)	693/729 (95%)	
	First Trimester (<	<u>93 day</u>			
			Vaccinate	Control	
	Enrolled		209	213	
	Excluded (not re	lated	1	0	
	to vaccination)				
	Aborted or stillb		6	5	
	Died at or after b	oirth	2	3	
	Second Trimester (94-187 days of gestation)				
	Second Trimester	(94-1			
	T 11 1		Vaccinate	Control	
	Enrolled	1 , 1	315	310	
	Excluded (not re	lated	2	2	
	to vaccination)				
	Aborted or stillb		7	9	
	Died at or after b		4	6*	
	*one death was fr	om a s	set of twins; the of	her was normal	
	Thind Trime actor (100 24	50 days of acetatic	n)	
	Third Trimester (188-250 days of gestation) Vaccinate Control		Control		
	Enrolled				
		0444	9	208	
	Aborted or stillb		3	4**	
	Died at of ditter of the				
	*one stillborn was from a set of twins; the other was normal **one dead was from a set of twins; the other was normal				
	one dead was n	ioni a	set of twills; the of	mer was normal	

213 1181.20 Page 8 of 9

USDA Approval Date	March 5, 2013

213 1181.20 Page 9 of 9